Cigall Kadoch - 31 Aug 2022 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Director
Signature
/s /Allan Reine, M.D., Attorney-in-Fact
Issuer symbol
FHTX
Transactions as of
31 Aug 2022
Net transactions value
$0
Form type
4
Filing time
02 Sep 2022, 08:07:29 UTC
Previous filing
22 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FHTX Common Stock 295,000 31 Aug 2022 Direct
holding FHTX Common Stock 3,329,379 31 Aug 2022 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FHTX Stock Options (Right to buy) 16,000 31 Aug 2022 Common Stock 16,000 $13.81 Direct
holding FHTX Stock Options (Right to buy) 12,530 31 Aug 2022 Common Stock 12,530 $9.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Cigall Kadoch is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Shares held by the Cigall Kadoch Revocable Trust of 2021, of which the Reporting Person is the sole trustee and sole current beneficiary.